FindTrial
Sign In

ART0380

DRUG3 trials

Sponsors

Artios Pharma Limited, Artios Pharma Ltd

Conditions

Acinar Cell CarcinomaAdvanced CancerAdvanced Solid TumorAdvanced or Metastatic Solid TumoursEndometrial CancerFallopian Tube CancerMetastatic CancerMetastatic Colorectal Cancer

Phase 1

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingNCT04657068
Artios Pharma LtdAcinar Cell Carcinoma, Advanced Cancer, Endometrial Cancer +6
Start: 2021-01-27End: 2028-06-01Target: 542Updated: 2026-07-30
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
RecruitingCTIS2024-511534-12-00
Artios Pharma LimitedAdvanced or Metastatic Solid Tumours
Start: 2025-06-10Target: 140Updated: 2025-10-28

Phase 2

Study of ART0380 in Patients With Biologically Selected Solid Tumors
TerminatedNCT05798611
Artios Pharma LtdAdvanced Solid Tumor, Metastatic Cancer, Recurrent Endometrial Cancer
Start: 2023-09-06End: 2025-05-27Updated: 2025-11-06

Related Papers

STELLA: A dose expansion of the ATR kinase inhibitor alnodesertib (ART0380) administered orally in combination with low-dose irinotecan to patients with advanced or metastatic CRC and PDAC.
Journal of Clinical Oncology2026-05-28
Abstract 1738: Alnodesertib (ART0380) in combination with irinotecan is highly efficacious in preclinical models of ATM null pancreatic cancer
Cancer Research2026-04-03
Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors
Cancer Research2025-04-251 citations
Abstract 2905: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors
Cancer Research2025-04-211 citations
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers
Journal of Medicinal Chemistry2024-12-049 citations
Abstract LB520: A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380)
Cancer Research2022-06-153 citations
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
2021-12-1569 citations